Applications of Gene Therapy - Challenges in Delivery of Therapeutic Genomics and Proteomics - page 321

[308] Schuening F, Longo WL, Atkinson ME, Zaboikin M, Kiem HP, Sanders J, et al.
Retrovirus-mediated transfer of the cDNA for human glucocerebrosidase into periph-
eral blood repopulating cells of patients with Gaucher's disease. Hum Gene Ther
1997;8:2143-60.
[309] Barranger JA, Rice EO, Swaney WP. Gene transfer approaches to the lysosomal storage
disorders. Neurochem Res 1999;24:601-15.
[310] Chuah MKL, Desire C, Vanden D. Gene therapy for hemophilia. J Gene Med 2001;
3:3-20.
[311] Fallaux FJ, Hoeben RC. Gene therapy for the hemophilias. Curr Opin Hematol 1996;
3:385-9.
[312] Pittman DD, Alderman EM, Tomkinson KN, Wang JH, Giles AR, Kaufman RJ.
Biochemical, immunological, and in vivo functional characterization of B-domain-
deleted factor VIII. Blood 1993;81:2925-35.
[313] Israel DI, Kaufman RJ. Retroviral-mediated transfer and amplification of a functional
human factor VIII gene. Blood 1990;75:1074-80.
[314] Hoeben RC, Fallaux FJ, Van Tilburg NH, Cramer SJ, Van Ormondt H, Briet E, et al.
Toward gene therapy for hemophilia A: long-term persistence of factor VIII-secreting
fibroblasts after transplantation into immunodeficient mice. Hum Gene Ther 1993;
4:179-86.
[315] Chuah MK, Vandendriessche T, Morgan RA. Development and analysis of retrovi-
ral vectors expressing human factor VIII as a potential gene therapy for hemophilia A.
Hum Gene Ther 1995;6:1363-77.
[316] Zatloukal K, Cotten M, Berger M, Schmidt W, Wagner E, Birnstiel ML. In vivo produc-
tion of human factor VIII in mice after intrasplenic implantation of primary fibroblasts
transfected by receptor-mediated, adenovirus-augmented gene delivery. Proc Natl Acad
Sci USA 1994;91:5148-52.
[317] Hoeben RC, Einerhand MP, Briet E, Van Ormondt H, Valerio D, Vander AJ. Toward
gene therapy in haemophilia A: retrovirus-mediated transfer of a factor VIII gene into
murine haematopoietic progenitor cells. Thromb Haemostasis 1992;67:341-5.
[318] Vanden-Driessche T, Vanslembrouck V, Goovaerts I, Zwinnen H, Vanderhaeghen ML,
Collen D, et al. Long-term expression of human coagulation factor VIII and correction
of hemophilia A after in vivo retroviral gene transfer in factor VIII deficient mice. Proc
Natl Acad Sci USA 1999;96:10379-84.
[319] Liu L, Mah C, Fletcher BS. Sustained FVIII expression and phenotypic correction of
hemophilia A in neonatal mice using an endothelial-targeted sleeping beauty transpo-
son. Mol Ther 2006;13:1006-15.
[320] Xu L, Nichols TC, Sarkar R, McCorquodale S, Bellinger DA, Ponder KP. Absence of a
desmopressin response after therapeutic expression of factor VIII in hemophilia A dogs
with liver-directed neonatal gene therapy. Proc Natl Acad Sci USA 2005;102:6080-85.
[321] Anson DS, Hock RA, Austen D, Smith KJ, Brownlee GG, Verma IM, et al. Towards
gene therapy for hemophilia B. Mol Biol Med 1987;4:11-20.
[322] Hortelano G, Al-Hendy A, Ofosu FA, Chang PL. Delivery of human factor IX in mice
by encapsulated recombinant myoblasts: a novel approach towards allogeneic gene
therapy of hemophilia B. Blood 1996;87:5095-103.
[323] Gerrard AJ, Austen DE, Brownlee GG. Recombinant factor IX secreted by transduced
human keratinocytes is biologically active. Br J Haematol 1996;95:561-3.
[324] Hao QL, Malik P, Salazar R, Tang H, Gordon EM, Kohn DB. Expression of biologi-
cally active human factor IX in human hematopoietic cells after retroviral vector-medi-
ated gene transduction. Hum Gene Ther 1995;6:873-80.